Integrity Compounding Pharmacy: The 2026 Trust Verification Guide

Introduction: One Search Term, Two Pharmacies, and a Bigger Question

A search for “integrity compounding pharmacy” returns results for two unrelated businesses. One is a triple-accredited pharmacy headquartered in Sandy Springs, Georgia, with a sister location in Tampa, Florida. The other is a Costa Mesa, California pharmacy formerly known as Westcliff Compounding Pharmacy. Same name, different companies.

Behind most of these searches is a more important question than which business is which: can this pharmacy be trusted with a medication? Patients, caregivers, and prescribers often type a pharmacy’s name because they want reassurance, not only an address.

This guide has two purposes. First, it separates the two “Integrity” businesses so readers reach the one they intend. Second, it treats the word “integrity” as a five-point verification framework that applies to any compounding pharmacy, whatever its name. The five pillars are:

1. Accreditation
2. Sourcing
3. Testing
4. Transparency
5. Regulatory compliance

The framework matters in 2026. Demand for compounded GLP-1 and weight-loss medications has drawn heavy scrutiny, and FDA enforcement activity this year shows that pharmacy-level quality cannot be assumed.

Which ‘Integrity Compounding Pharmacy’ Is Being Searched For?

Before the trust framework, it helps to sort out the names. The two businesses below are separate, unaffiliated companies that share a name, and that overlap regularly confuses searchers.

The Georgia-Based Integrity Compounding Pharmacy (Sandy Springs, GA + Tampa, FL)

• Founded: 2013
• Headquarters: Sandy Springs, Georgia
• Website domain: mixwithintegrity.com
• Team size: 11 to 50 employees
• Volume: an average of 400-500 prescriptions per day, covering sterile, non-sterile, hazardous, and non-hazardous medications
• Licensing: licensed in more than 40 states, with nationwide shipping for most medications
• Sister location: Carrollwood Compounding Center in Tampa, Florida, which also operates under the Integrity Compounding Pharmacy brand

In February 2026, the pharmacy announced triple accreditation from the Accreditation Commission for Health Care (ACHC) through its PCAB program. The pharmacy reported it was the first in its region to reach this milestone. The accreditation spans three categories: non-sterile compounding (USP <795>), sterile compounding, and hazardous drug handling.

Public feedback is mixed by audience. Patient-facing reviews are strong, generally 4.3 to 4.8 stars across platforms. Employee reviews on Indeed average around 1.8 out of 5 on management and culture. The gap is a reminder that how patients experience a pharmacy and how it runs internally are separate signals.

The Costa Mesa, CA ‘Integrity Compounding’ (Formerly Westcliff Compounding Pharmacy)

The California business began in 2011, when pharmacists Mike Pavlovich and John O’Connell formed Westcliff Compounding Pharmacy. It later rebranded as Integrity Compounding.

It operates independently of the Georgia pharmacy, with no corporate, ownership, or operational relationship between them.

Before submitting a prescription or personal health information, patients and providers should confirm three details:

• The physical location
• The state of licensure
• The website domain

Why Brand-Name Confusion Is Common in the Compounding Industry

Compounding pharmacies often choose names built on trust words such as Integrity, Precision, Care, or Wellness. That makes overlap between unrelated businesses likely.

It also shows why trusting a pharmacy based on its name is risky. A name can suggest quality, but it cannot prove it. Patients need a repeatable verification method that works no matter what the sign on the door says, and the five-point integrity checklist provides one.

Why ‘Integrity’ Needs to Be a Framework, Not Just a Brand Word

Compounded medications do not go through the standard FDA drug approval process. Because of that, the safety of a compounded preparation depends heavily on the processes inside the pharmacy that makes it.

The clearest example of what happens when those processes fail is the 2012 New England Compounding Center (NECC) fungal meningitis outbreak. According to the CDC, contaminated products caused 64 deaths and sickened 753 people. Investigators found that NECC had violated its state license by functioning as a drug manufacturer. It was producing drugs for broad distribution instead of filling individual prescriptions.

The tragedy led directly to the Drug Quality and Security Act, which created the modern 503A/503B regulatory framework. One gap remains important today: 503A pharmacies are not routinely FDA-inspected unless there is a complaint. Third-party accreditation fills much of that oversight gap. This is why verification carries more weight than brand reputation.

The risk is not only historical. Enforcement actions in 2026, covered below, show that integrity failures still happen.

The Five-Point Integrity Checklist: How to Vet Any Compounding Pharmacy

The checklist below is a universal framework. Patients and providers can apply it to any compounding pharmacy. It is not limited to businesses named “Integrity.”

The current baseline for all five points was set by two milestones:

• USP compounding chapters <795>, <797>, and <800> became fully enforceable on November 1, 2023.
• PCAB’s updated standards, which incorporate the USP <795> revisions, took effect on June 1, 2024.

1. Accreditation: Look for PCAB/ACHC or NABP Verification

What PCAB covers. PCAB accreditation, administered by ACHC, verifies that a pharmacy’s processes meet USP <795>, <797>, and <800> standards at the time of the survey.

How rare it is. Of more than 7,500 compounding pharmacies in the U.S., only about 68 hold PCAB accreditation. That is fewer than 1%.

A complementary pathway. The National Association of Boards of Pharmacy (NABP) runs the Verified Pharmacy Program (VPP). Its inspectors check compliance with USP <795>, <797>, <800>, and <825>.

The key caveat. Industry legal commentary stresses that PCAB verifies process standards at a point in time. It does not provide immunity from a future FDA inspection, a PBM audit, or a state board complaint.

Growing state enforcement. States are increasingly tying accreditation to licensure:

• Washington and Ohio now require PCAB accreditation for nonresident compounding pharmacy licensure.
• Kentucky began active enforcement of the revised USP <795>, <797>, and <800> standards on January 1, 2026.

Actionable tip: Patients should ask the pharmacy three questions:

• Which accreditation body certified it?
• In which categories (non-sterile, sterile, hazardous)?
• Can it share the certificate?

They should then confirm the answer in the accrediting body’s public directory.

2. Sourcing: Where Do the Raw Ingredients Come From?

Compounded drugs are made from active pharmaceutical ingredients (APIs) that do not go through the review applied to standard commercial drug manufacturing. The quality of those raw ingredients directly affects the finished medication.

The FDA has added safeguards in this area:

• 2025 “green list”: an initiative to confirm that compounders source APIs from facilities the agency has inspected or evaluated.
• April 2026 clarification: the FDA defined an “essentially a copy” drug as one with the same API as a commercially available product, in a similar strength or route of administration. This is especially relevant for patients using compounded GLP-1s or other high-demand drugs.

Actionable tip: Patients should ask whether the pharmacy sources from FDA-inspected and cleared vendors, and whether it checks API sourcing against the FDA’s green list.

3. Testing: Independent Verification of Potency and Sterility

Independent third-party testing catches potency, sterility, and contamination problems before medications reach patients.

The February 2026 FDA warning letter to Boothwyn Pharmacy shows what happens when testing rigor breaks down. The letter cited:

• Sterility failures
• Subpotent injectable and ophthalmic drugs
• Insanitary production conditions

Actionable tip: Patients should ask whether sterile preparations undergo independent third-party potency and sterility testing, and whether results are available on request.

4. Transparency: Turnaround Times, Communication, and Recall Handling

Transparency means clear, proactive communication about:

• Turnaround expectations
• Shipping availability
• Formulation changes
• Recalls

Reliable pharmacies communicate clearly and handle recalls properly as part of basic patient safety practice.

Actionable tip: Patients should request the turnaround window in writing (for example, 1-2 business days) and ask how the pharmacy would notify patients and providers if a recall or quality issue occurred.

5. Regulatory Compliance: State Licensing and 503A/503B Status

There are two main types of compounders:

Type	What it does	FDA oversight
503A	Compounds patient-specific prescriptions	Not routinely FDA-inspected absent a complaint
503B (outsourcing facility)	Can produce larger batches	Registered with the FDA

The type matters for the kind of prescription being filled. Because 503A pharmacies are not routinely inspected by the FDA, verifying state licensing is essential.

The September 2026 FDA warning letter to Empower Pharmacy, a Texas-based 503A facility, is a cautionary example. The FDA cited it for manufacturing “inordinate amounts” of weight-loss drugs that were essentially copies of brand-name products. Inspectors also found:

• Inadequate smoke studies for ISO 5 airflow
• Media fills not run under the most challenging conditions
• Media fill records transcribed onto a new form with no audit trail

Actionable tip: Patients should verify the pharmacy’s licenses directly on each relevant state board of pharmacy website, especially when medications ship across state lines.

Case Study: The Real Integrity Compounding Pharmacy as a Checklist in Action

The Sandy Springs pharmacy is a genuine positive example of the checklist at work. It is presented here as an illustration, not as a competitor to criticize.

• Accreditation: Its February 2026 triple PCAB/ACHC accreditation (non-sterile, sterile, and hazardous drug handling) places it among the roughly 1% of U.S. compounding pharmacies with PCAB status.
• Scale: Filling 400-500 prescriptions per day shows operational capacity consistent with accredited, high-volume compounding.
• Regulatory reach: Licensure in more than 40 states shows how multi-state licensing works in practice.
• Honest nuance: Strong patient reviews alongside weaker employee reviews show that accreditation and service quality do not always line up with internal culture. No single signal tells the whole story.

The case study shows what real, verifiable integrity signals look like. The same checklist should still be applied to any pharmacy under consideration, including this one.

When the Checklist Flags Risk: What 2026 Enforcement Actions Teach Patients

The Empower and Boothwyn warning letters show that integrity failures remain an active risk, not a problem solved after NECC.

Both were 503A facilities operating under the same general framework described in the checklist. They failed on different pillars:

• Empower: manufacturing scope and copying of brand-name products
• Boothwyn: testing and sterility

Accreditation is valuable, but it is not a permanent guarantee. Industry legal commentary is clear that PCAB verifies process standards and does not protect against future violations or FDA inspections. Verification should therefore be ongoing, not a one-time check. Patients and providers should look for recent FDA warning letters on any pharmacy under consideration, in addition to confirming accreditation.

How to Apply the Integrity Checklist When Searching for a Compounding Pharmacy

A practical sequence:

1. Confirming the exact business entity and location, including the website domain.
2. Verifying accreditation in the PCAB/ACHC or NABP directories.
3. Asking about API sourcing, including FDA-inspected vendors and green list alignment.
4. Asking about third-party testing, especially for sterile preparations.
5. Confirming state licensing for the patient’s state.
6. Checking for recent FDA warning letters or state board actions.

Patients may find it helpful to keep a short list of these questions ready. They can be asked of any pharmacy, including a compounding partner recommended by a provider, before a prescription is submitted. The process works whether the pharmacy is called “Integrity,” “Nationwide,” or anything else.

Where Nationwide Compounding Rx® Fits: Meeting the Same Bar, With Broader Reach

Nationwide Compounding Rx®, based in Scottsdale, Arizona, meets the same five-point bar shown in the Georgia case study. It does not claim to be the only pharmacy that does.

• Accreditation: PCAB accredited and USP 800 compliant, with more than 40 years of combined team experience.
• Sourcing: High-grade chemicals sourced exclusively from FDA-inspected and cleared vendors.
• Testing: Independent third-party testing verifies quality and consistency across sterile and non-sterile formulations.
• Transparency: A stated 1-2 business day turnaround, with same-day pickup available for some medications. Separate secure Provider and Patient Portals support order tracking, refills, and communication.
• Regulatory compliance: A published three-tier state map shows where it is fully licensed, where it is licensed for non-sterile only (sterile pending), and where licensing is pending or not held.

Its differences lie in reach and breadth. Nationwide Compounding Rx® pairs a multi-state shipping footprint and clear turnaround commitments with a range of specialties:

• GLP-1/peptide support
• Bioidentical hormone replacement therapy (BHRT), with formulas adjustable at each refill based on lab results
• Pain management
• Dermatology
• Pediatrics
• Sports medicine

These services are delivered through a structured provider partnership model: Connect, Collaborate, Create, Care.

Conclusion: Integrity Is a Verification Habit, Not Just a Business Name

Two practical takeaways emerge from this guide:

• Disambiguation: the Sandy Springs/Tampa Integrity Compounding Pharmacy and the Costa Mesa Integrity Compounding are separate, unaffiliated businesses.
• A reusable framework: accreditation, sourcing, testing, transparency, and regulatory compliance can be used to evaluate any compounding pharmacy.

Accreditation and reputation are necessary, but they are not enough on their own. Enforcement activity in 2026 shows that verification needs to continue over time. Patients and providers who apply the checklist consistently are better protected, whatever pharmacy name appears in their search results.

An Open Invitation to Verify Nationwide Compounding Rx®

Nationwide Compounding Rx® invites patients and providers to apply the five-point checklist to its own operations. That includes reviewing its PCAB accreditation, USP 800 compliance, sourcing practices, and state licensing map.

To ask verification questions or begin a partnership:

• Phone: (480) 499-8379, Monday through Friday, 7:00 AM to 3:30 PM (Arizona time)
• Online: the secure Provider or Patient Portal at nationwidecompounding.com
• Email inquiries: answered within one business day

Healthcare providers evaluating a compounding partner can explore the Connect, Collaborate, Create, Care process to see whether Nationwide Compounding Rx® meets their practice’s standards.